Literature DB >> 22442904

Defunctioning stoma and anastomotic leak rate after total mesorectal excision with coloanal anastomosis in the context of PROCARE.

K Beirens1, F Penninckx.   

Abstract

BACKGROUND: Anastomotic leakage (AL) after total mesorectal excision is a major adverse event. Construction of a defunctioning stoma (DS) reduces the morbidity of AL. This study aims to illustrate the AL rate and its related morbidity with and without primary stoma formation in the context of a Belgian project, PROCARE.
METHODS: Between January 2006 and March 2011, 1912 patients who underwent elective TME with colo-anal anastomosis for invasive rectal adenocarcinoma up to 15 cm above the anal verge were registered. A primary DS was constructed in 1183 patients (62%). Early clinical AL rate, AL-related re-operation rate, length of stay (LoS), in-hospital mortality were analysed.
RESULTS: In patients without leak, mortality was 1.1% and the mean LoS was 14.7 days. AL occurred in 6.5%, varying from 0%-25% between participating centres. In patients with AL, mortality was 4.8% (p < 0.001). In the presence of a primary DS, AL rate was 4.3%, requiring re-operation under narcosis in 78% with no mortality, resulting in a mean LoS of 30.4 days. In the absence of a primary DS, AL rate was 10.2%, requiring re-operation under narcosis in 93% with a mortality of 8.1% and a mean LoS of 33.4 days. Analysis per centre showed a weak relation between percentage of DS construction and AL rate.
CONCLUSION: Construction of a primary DS significantly reduced the incidence of early AL, re-operation rate, and mortality. Although technical aspects of colo-anal anastomosis are of paramount importance, construction of a DS at primary surgery has to be considered by those teams with high early AL rate and/or high AL related mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22442904     DOI: 10.1080/00015458.2012.11680789

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  7 in total

Review 1.  Role of protective stoma in low anterior resection for rectal cancer: a meta-analysis.

Authors:  Sheng-Wen Wu; Cong-Chao Ma; Yu Yang
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

2.  The REAL (REctal Anastomotic Leak) score for prediction of anastomotic leak after rectal cancer surgery.

Authors:  A Arezzo; M Migliore; P Chiaro; S Arolfo; C Filippini; D Di Cuonzo; R Cirocchi; M Morino
Journal:  Tech Coloproctol       Date:  2019-06-25       Impact factor: 3.781

3.  Meta-analysis of defunctioning stoma in low anterior resection with total mesorectal excision for rectal cancer: evidence based on thirteen studies.

Authors:  Wen-long Gu; Sheng-wen Wu
Journal:  World J Surg Oncol       Date:  2015-01-24       Impact factor: 2.754

4.  Application of the cuff rectum drainage tube in total mesorectal excision for low rectal cancer: A retrospective case-controlled study.

Authors:  Weipeng Ye; Zhipeng Zhu; Gang Liu; Borong Chen; Junjie Zeng; Jin Gao; Shengjie Wang; Hejie Cai; Guoxing Xu; Zhengjie Huang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

5.  Risk Factors of Delayed Recovery of Gastrointestinal Function After Ileostomy Reversal for Rectal Cancer Patients.

Authors:  Lili Chu; Hui Wang; Suyu Qiu; Biyan Shao; Jia Huang; Qiyuan Qin; Yanjiong He; Jing Xue; Xiaoyan Li; Xiaoyan Huang; Rongkang Huang
Journal:  Cancer Manag Res       Date:  2021-06-29       Impact factor: 3.989

6.  Systematic review of anastomotic leakage rate according to an international grading system following anterior resection for rectal cancer.

Authors:  Zhi-Jie Cong; Liang-Hao Hu; Zheng-Qian Bian; Guang-Yao Ye; Min-Hao Yu; Yun-He Gao; Zhao-Shen Li; En-Da Yu; Ming Zhong
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

7.  Prevention of anastomotic fistula formation after low-position Dixon Operation.

Authors:  Feng Gao; Ming Xu; Feng Song; Xin Zhang; Yong Zhao
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.